Literature DB >> 25048366

Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.

Anne Mwirigi1, Sofia Galli, Clodagh Keohane, Kavita Raj, Deepti H Radia, Claire N Harrison, Donal P McLornan.   

Abstract

Entities:  

Keywords:  Janus Kinase inhibitors; blast phase; hypomethylating agents; myeloproliferative neoplasms

Mesh：

Substances：

Year:  2014        PMID： 25048366     DOI： 10.1111/bjh.13046

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

Review 1.  Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.

Authors:  Robyn M Scherber; Ruben A Mesa
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life.

Authors:  Leslie Padrnos; Ruben A Mesa
Journal:  Oncology (Williston Park)       Date:  2017-07-15       Impact factor: 2.990

3.  Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Authors:  Raajit K Rampal; John O Mascarenhas; Heidi E Kosiorek; Leah Price; Dmitriy Berenzon; Elizabeth Hexner; Camille N Abboud; Marina Kremyanskaya; Rona Singer Weinberg; Mohamed E Salama; Kamal Menghrajani; Vesna Najfeld; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Judith D Goldberg; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-12-26

4.  Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Authors:  Kiran Naqvi; Naval Daver; Naveen Pemmaraju; Prithviraj Bose; Guillermo Garcia-Manero; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2016-08-05

5.  Guidance on changing therapy choice in myelofibrosis.

Authors:  Donal P McLornan; Claire N Harrison
Journal:  Blood Adv       Date:  2020-02-25

Review 6.  Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.

Authors:  Bing Li; John O Mascarenhas; Raajit K Rampal
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 7.  Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.

Authors:  Robyn M Scherber; Ruben A Mesa
Journal:  Blood Rev       Date:  2020-05-30       Impact factor: 8.250

Review 8.  Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.

Authors:  Andrew T Kuykendall; Nathan P Horvat; Garima Pandey; Rami Komrokji; Gary W Reuther
Journal:  Cancers (Basel)       Date:  2020-08-14       Impact factor: 6.639

Review 9.  The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.

Authors:  Graeme Greenfield; Suzanne McPherson; Ken Mills; Mary Frances McMullin
Journal:  J Transl Med       Date:  2018-12-17       Impact factor: 5.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.